High-risk stage II colon cancer after curative resection

Journal of Surgical Oncology

Volumn 104, Issue 1, 2011, Pages 45-52

  Sato, Harunobu ^a,b   Maeda, Koutarou ^a,b   Sugihara, Kenichi ^a,c   Mochizuki, Hidetaka ^a,d   Kotake, Kenjiro ^a,e   Teramoto, Tetsuo ^a,f   Kameoka, Shingo ^a,g   Saito, Yukio ^a,h   Takahashi, Keiichi ^a,i   Hirai, Takashi ^a,j   Ohue, Masayuki ^a,k   Shirouzu, Kazuo ^a,l   Sakai, Yoshiharu ^k,m   Watanabe, Toshiaki ^a,n   Hirata, Koichi ^a,o   Hatakeyama, Katsuyoshi ^a,p  

^a Japanese Study Group for Postoperative Follow up of Colorectal Cancer   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e TOCHIGI CANCER CENTER   (Japan)

^f TOHO UNIVERSITY   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

ⁱ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^l KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m KYOTO UNIVERSITY   (Japan)

ⁿ TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o SAPPORO MEDICAL UNIVERSITY   (Japan)

^p NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

more..

Author keywords

Adjuvant chemotherapy; Colon carcinoma; Curative resection; Prognostic factors

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURGERY; COLON CANCER; COLON RESECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EMERGENCY SURGERY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 79958156608     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21914     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, et al.: Cancer statistics. CA Cancer J Clin 2004;54:8-29.
2. Kotake K, Honjo S, Sugihara K, et al.: Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 2003;46:32-43.
3. American Joint Committee on Cancer: AJCC cancer stageing manual, 6th edition. New York, USA: Springer; 2002. pp. 113-124.
4. Jessup JM, McGinnis LS, Steele GD Jr, et al.: The National Cancer Data Base. Report on colon cancer. Cancer 1996;78: 918-926. (Pubitemid 26268626)
5. Schrag D, Rifas-Shiman S, Saltz L, et al.: Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;19:3999-4005.
6. IMPACT B2: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer trials investigators. J Clin Oncol 1999;17: 1356-1363.
7. Gill S, Loprinzi CL, Sargent DJ, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer. J Clin Oncol 2004;22:1797-1806. (Pubitemid 41095169)
8. Benson AB 3rd, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22: 3408-3419. (Pubitemid 41103700)
9. National Comprehensive Cancer Network. Engstrom PF, Arnoletti JP, Benson AB 3rd, et al.: NCCN clinical practice guidelines in oncology: colon cancer. V.3.2010. http://www.nccn.org/, 2010.
10. Japanese Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma. Tokyo, Japan: Kanehara & Co., Ltd.; 1997.
11. Kodaira S, Kikuchi K, Yasutomi M, et al.: Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No. 7 Group of the Japanese Foundation for Multidisciplinary Treatment of cancer. Int J Clin Oncol 1998;3:357-364. (Pubitemid 29091208)
12. Kato T, Ohashi Y, Nakazato H, et al.: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbeck's Arch Surg 2002;386:575-581. (Pubitemid 34285637)
13. Akasu T, Moriya Y, Yasuo O, et al.: Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomaized controlled trial. Jpn J Clin Oncol 2006;36:237-244.
14. Park IJ, Choi G, Lim KH, et al.: Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers. Ann Surg Oncol 2008;15:3478-3483.
15. Gertler R, Rosenberg R, Schuster T, et al.: Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy. Eur J Cancer 2009;45:2992-2999.
16. Kobayashi H, Mochizuki H, Sugihara K, et al.: Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 2007;141:67-75. (Pubitemid 44918081)
17. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin- modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 1993;11: 1879-1887. (Pubitemid 23304611)
18. Yano H, Saito Y, Kirihara Y, Takashima J: Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2006;49:1867-1877. (Pubitemid 44853444)
19. Sargent D, Sobrero A, Grothey A, et al.: Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-877.
20. Marsoni S: International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. Semin Oncol 2001;28:14-19.
21. QUASAR Collaborative Group: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 2007;370:2020-2029.
22. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355. (Pubitemid 29220839)
23. Haller DG, Catalapo PJ, Macdonald JS, Mayer RJ: Phase III study of fluorouracil, leucovorin and levamisole in high risk stage II and III colon cancer: final report of intergroup 0089. J Clin Oncol 2005;23:8671-8678. (Pubitemid 46211510)
24. International multicentre pooled analysis of colon cancer trials (IMPACT): Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-944.
25. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Eng J Med 2005;352:2696-2704. (Pubitemid 41007824)
26. Kuebler JP, Wieand HS, O'Connell MJ, et al.: Oxaliplatin combined with weekly bolus fliorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSAB P C-07. J Clin Oncol 2007;25:2198-2204. (Pubitemid 46954643)
27. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med 2004;350:2343-2351. (Pubitemid 38702845)
28. de Gramont A, Boni C, Navarro M, et al.: Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years. J Clin Oncol 2007;25:18S, (suppl; abstr 4007).
29. Cheeseman SL, Joel SP, Chester JD, et al.: A "modified de Gramont" regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Brit J Cancer 2002;87:393-399. (Pubitemid 34983562)
30. Welles L, Hochster H, Ramanathan R, et al.: Preliminary results of a randomized study of safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer ("Tree" study). J Clin Oncol 2004;22:14S, (suppl; abstr 3537).